Antoine Hollebecque researcher
Hollebecque, Antoine, 1979-....
VIAF ID: 198923711 (Personal)
Permalink: http://viaf.org/viaf/198923711
Preferred Forms
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer | |
Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib | |
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. | |
Development and validation of a bedside score to predict early death in cancer of unknown primary patients | |
Development of a score that predicts survival among patients with bone metastasis revealing solid tumor | |
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer | |
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. | |
Evolution à 5 ans de la stéatose et de la fibrose hépatique chez les obèses morbides traités par chirurgie bariatrique | |
The evolution of severe steatosis after bariatric surgery is related to insulin resistance | |
Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. | |
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors | |
First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient | |
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma | |
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients | |
Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France | |
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. | |
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? | |
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. | |
LONG-TERM SURVIVAL IN PATIENTS RESPONDING TO ANTI-PD-1/PD-L1 THERAPY AND DISEASE OUTCOME UPON TREATMENT DISCONTINUATION | |
Modifying phase I methodology to facilitate enrolment of molecularly selected patients | |
Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control | |
Peroxisome proliferator-activated receptors in HBV-related infection | |
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. | |
Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma | |
Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume | |
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease | |
Systemic treatment of pancreatic cancer revisited | |
Targeted therapy-induced radiation recall | |
Tumor assessment criteria in phase I trials: beyond RECIST. | |
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity |